Hospira CEO on Personal Involvement
This article was originally published in RPM Report
One of the foundations for resolving repeat QC problems is convincing FDA that compliance is the top priority of senior management. When FDA officials cannot reach senior management or sense a lack of commitment at the top, the assumption is that the culture and organizational structure of the firm
You may also be interested in...
Hospira’s new CEO Mike Ball was charting a global expansion and touting a move into biosimilars. Then the lingering quality control discussions with FDA caught up with the company and forced their way to the top of his agenda. That may be an important step for the company in the long-term.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
Multiple simultaneous sponsors, foreshortened regulatory reviews, and a packet of unanswered post-approval efficacy issues make for what should be very competitive – and inherently comparative – post-market assessment period for the upcoming SARS-CoV-2 vaccines.